Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96EQ8

UPID:
RN125_HUMAN

ALTERNATIVE NAMES:
RING finger protein 125; T-cell RING activation protein 1

ALTERNATIVE UPACC:
Q96EQ8; Q9NX39

BACKGROUND:
The E3 ubiquitin-protein ligase RNF125, known for its roles in immune regulation, mediates the ubiquitination and degradation of several proteins critical for immune response and cellular homeostasis. By targeting proteins such as RIGI, MAVS/IPS1, IFIH1/MDA5, JAK1, and p53/TP53 for degradation, RNF125 serves as a negative regulator of type I interferon production and a positive regulator of T-cell activation.

THERAPEUTIC SIGNIFICANCE:
RNF125's link to Tenorio syndrome, a genetic condition with distinct physical and cognitive manifestations, underscores its therapeutic potential. Exploring the functions of E3 ubiquitin-protein ligase RNF125 could lead to innovative treatments for related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.